1st Course on Urothelial Cancers 2023: tumor heterogeneity and therapeutic resistance

The aim of this course is to provide a practical and up-to-date overview of the latest research and clinical developments in urothelial cancer, including muscle-invasive and non-muscle invasive bladder cancers, upper urinary tract urothelial carcinomas, and their metastases. In so doing, we aim to a) promote a consensus understanding of the current optimal treatment strategies for these diseases, b) provide practical knowledge and a clinical perspective of the diseases and how they are treated, c) promote an enhanced mechanistic understanding of the diseases and the methodologies used to study them, and d) provide an industry perspective to share how new treatments are developed.

Keynote speakers

Lars DYRSKJØT - DK

Cours en English

Registration deadline

October 29th 2023

Speakers
Plus d'informations
Documents

Intervenants

Keynote speaker : Lars DYRSKJØT - DK

Ferran ALGABA - ES

Yves ALLORY - FR

Claire Béraud - FR

Isabelle BERNARD-PIERROT - FR

Julia BONASTRE - FR

Lori CIREFICE - FR

Lars DYRSKJØT - DK

Aude FLECHON - FR

Christophe GINESTIER - FR

Nadine HOUEDE - FR

Molly INGERSOLL - FR

William KIM - US

Florence LE CALVEZ-KELM - FR

Seth LERNER - US

Yohann LORIOT - FR

Núria MALATS - ES

Yann NEUZILLET - FR

Remy NICOLLE - FR

François RADVANYI - FR

Morgan ROUPRÊT - FR

Mark RUBIN - CH

Florian SCOTTÉ - FR

Roland SEILER - CH

Gottfrid SJÖDAHL - SE

Eric TARTOUR - FR

This list of speakers may still change

Plus d’informations

Objectifs

Upon successful completion of this course, students will be able to:

1) Discuss new discoveries and preclinical models in urothelial cancer research regarding tumor heterogeneity and therapeutic resistance

2) Explain cutting-edge preclinical research techniques, including single-cell and spatial omics approaches, and asses their clinical potential for urothelial cancers

3) Describe the stages of drug and technology development

4) Compare and contrast current and developing treatments in urothelial cancer care

5) As a team, formulate a plan for cancer care, given a particular urothelial cancer case

6) Discuss and debate ethical issues related to urothelial cancer treatments and research